25 results on '"Bergman, Richard N."'
Search Results
2. The Measurement of Insulin Clearance.
- Author
-
Piccinini, Francesca and Bergman, Richard N.
- Subjects
- *
INSULIN , *TYPE 2 diabetes , *GLUCOSE metabolism , *ESTIMATION theory , *DIAGNOSIS of endocrine diseases , *LIVER , *BLOOD sugar , *BIOTRANSFORMATION (Metabolism) , *C-peptide , *ANIMALS , *INSULIN resistance - Abstract
Insulin clearance has recently been highlighted as a fundamental aspect of glucose metabolism, as it has been hypothesized that its impairment could be related to an increased risk of developing type 2 diabetes. This review focuses on methods used to calculate insulin clearance: from the early surrogate indices employing C-peptide:insulin molar ratio, to direct measurement methods used in animal models, to modeling-based techniques to estimate the components of insulin clearance (hepatic versus extrahepatic). The methods are explored and interpreted by critically highlighting advantages and limitations. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain.
- Author
-
Scarlett, Jarrad M., Kenjiro Muta, Brown, Jenny M., Rojas, Jennifer M., Matsen, Miles E., Acharya, Nikhil K., Secher, Anna, Ingvorsen, Camilla, Jorgensen, Rasmus, Høeg-Jensen, Thomas, Stefanovski, Darko, Bergman, Richard N., Piccinini, Francesca, Kaiyala, Karl J., Masakazu Shiota, Morton, Gregory J., Schwartz, Michael W., Muta, Kenjiro, and Shiota, Masakazu
- Subjects
PANCREATIC beta cells ,FIBROBLAST growth factors ,TYPE 2 diabetes ,INSULIN resistance ,HYPERGLYCEMIA ,BRAIN ,GROWTH factors ,HYPOGLYCEMIC agents ,ANIMALS ,BLOOD sugar ,DIABETES ,GLUCOSE tolerance tests ,INSULIN ,POLYMERASE chain reaction ,RATS ,TRANSFERASES ,THERAPEUTICS - Abstract
We recently reported that in rodent models of type 2 diabetes (T2D), a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) induces remission of hyperglycemia that is sustained for weeks. To clarify the peripheral mechanisms underlying this effect, we used the Zucker diabetic fatty fa/fa rat model of T2D, which, like human T2D, is characterized by progressive deterioration of pancreatic β-cell function after hyperglycemia onset. We report that although icv FGF1 injection delays the onset of β-cell dysfunction in these animals, it has no effect on either glucose-induced insulin secretion or insulin sensitivity. These observations suggest that FGF1 acts in the brain to stimulate insulin-independent glucose clearance. On the basis of our finding that icv FGF1 treatment increases hepatic glucokinase gene expression, we considered the possibility that increased hepatic glucose uptake (HGU) contributes to the insulin-independent glucose-lowering effect of icv FGF1. Consistent with this possibility, we report that icv FGF1 injection increases liver glucokinase activity by approximately twofold. We conclude that sustained remission of hyperglycemia induced by the central action of FGF1 involves both preservation of β-cell function and stimulation of HGU through increased hepatic glucokinase activity. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Hepatic but Not Extrahepatic Insulin Clearance Is Lower in African American Than in European American Women.
- Author
-
Piccinini, Francesca, Polidori, David C., Gower, Barbara A., and Bergman, Richard N.
- Subjects
INSULIN ,AFRICAN American women ,EUROPEAN Americans ,ETHNIC differences ,AFRICAN Americans ,C-peptide ,BLACK people ,BLOOD sugar ,GLUCOSE tolerance tests ,LIVER ,MATHEMATICAL models ,TYPE 2 diabetes ,RESEARCH funding ,WHITE people ,THEORY - Abstract
African Americans (AAs) tend to have higher plasma insulin concentrations than European Americans (EAs); the increased insulin concentrations have been attributed to increased secretion and/or decreased insulin clearance by liver or other tissues. This work characterizes the contributions of hepatic versus extrahepatic insulin degradation related to ethnic differences between AAs and EAs. By using a recently developed mathematical model that uses insulin and C-peptide measurements from the insulin-modified, frequently sampled intravenous glucose tolerance test (FSIGT), we estimated hepatic versus extrahepatic insulin clearance in 29 EA and 18 AA healthy women. During the first 20 min of the FSIGT, plasma insulin was approximately twice as high in AAs as in EAs. In contrast, insulin was similar in AAs and EAs after the 20-25 min intravenous insulin infusion. Hepatic insulin first-pass extraction was two-thirds lower in AAs versus EAs in the overnight-fasted state. In contrast, extrahepatic insulin clearance was not lower in AAs than in EAs. The difference in insulin degradation between AAs and EAs can be attributed totally to liver clearance. The mechanism underlying reduced insulin degradation in AAs remains to be clarified, as does the relative importance of reduced liver clearance to increased risk for type 2 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Indirect Regulation of Endogenous Glucose Production by Insulin: The Single Gateway Hypothesis Revisited.
- Author
-
Bergman, Richard N. and Iyer, Malini S.
- Subjects
- *
PHYSIOLOGICAL transport of insulin , *BLOOD sugar , *LIPOLYSIS , *LIPOTROPIN , *CAPILLARIES - Abstract
On the basis of studies that investigated the intraportal versus systemic insulin infusion and transendothelial transport of insulin, we proposed the "single gateway hypothesis," which supposes an indirect regulation of hepatic glucose production by insulin; the rate-limiting transport of insulin across the adipose tissue capillaries is responsible for the slow suppression of free fatty acids (FFAs), which in turn is responsible for delayed suppression of hepatic endogenous glucose production (EGP) during insulin infusion. Preventing the fall in plasma FFAs during insulin infusion either by administering intralipids or by inhibiting adipose tissue lipolysis led to failure in EGP suppression, thus supporting our hypothesis. More recently, mice lacking hepatic Foxo1 in addition to Akt1 and Akt2 (L-AktFoxo1TKO), all required for insulin signaling, surprisingly showed normal glycemia. Inhibiting the fall of plasma FFAs in these mice prevented the suppression of EGP during a clamp, reaffirming that the site of insulin action to control EGP is extrahepatic. Measuring whole-body turnover rates of glucose and FFAs in L-AktFoxo1TKO mice also confirmed that hepatic EGP was regulated by insulin-mediated control of FFAs. The knockout mouse model in combination with sophisticated molecular techniques confirmed our physiological findings and the single gateway hypothesis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Evidence That the Sympathetic Nervous System Elicits Rapid, Coordinated, and Reciprocal Adjustments of Insulin Secretion and Insulin Sensitivity During Cold Exposure.
- Author
-
Morton, Gregory J., Kenjiro Muta, Kaiyala, Karl J., Rojas, Jennifer M., Scarlett, Jarrad M., Matsen, Miles E., Nelson, Jarrell T., Acharya, Nikhil K., Piccinini, Francesca, Stefanovski, Darko, Bergman, Richard N., Taborsky Jr., Gerald J., Kahn, Steven E., Schwartz, Michael W., Muta, Kenjiro, and Taborsky, Gerald J Jr
- Subjects
SYMPATHETIC nervous system ,INSULIN ,HOMEOSTASIS ,GLUCOSE tolerance tests ,ADRENERGIC receptors ,PHENTOLAMINE ,ADRENERGIC alpha blockers ,ANIMAL experimentation ,ANIMALS ,BLOOD sugar ,COLD (Temperature) ,INSULIN resistance ,RATS ,RESEARCH funding ,GLUCOSE clamp technique ,PHARMACODYNAMICS - Abstract
Dynamic adjustment of insulin secretion to compensate for changes of insulin sensitivity that result from alteration of nutritional or metabolic status is a fundamental aspect of glucose homeostasis. To investigate the role of the brain in this coupling process, we used cold exposure as an experimental paradigm because the sympathetic nervous system (SNS) helps to coordinate the major shifts of tissue glucose utilization needed to ensure that increased thermogenic needs are met. We found that glucose-induced insulin secretion declined by 50% in rats housed at 5°C for 28 h, and yet, glucose tolerance did not change, owing to a doubling of insulin sensitivity. These potent effects on insulin secretion and sensitivity were fully reversed by returning animals to room temperature (22°C) for 4 h or by intravenous infusion of the α-adrenergic receptor antagonist phentolamine for only 30 min. By comparison, insulin clearance was not affected by cold exposure or phentolamine infusion. These findings offer direct evidence of a key role for the brain, acting via the SNS, in the rapid, highly coordinated, and reciprocal changes of insulin secretion and insulin sensitivity that preserve glucose homeostasis in the setting of cold exposure. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Insulin access to skeletal muscle is impaired during the early stages of diet-induced obesity.
- Author
-
Broussard, Josiane L., Castro, Ana V.B., Iyer, Malini, Paszkiewicz, Rebecca L., Bediako, Isaac Asare, Szczepaniak, Lidia S., Szczepaniak, Edward W., Bergman, Richard N., and Kolka, Cathryn M.
- Subjects
DIET ,INSULIN resistance ,HYPERINSULINISM ,HIGH-fat diet ,OBESITY ,ADIPOSE tissues ,ANIMAL experimentation ,BLOOD sugar ,DOGS ,GLUCOSE tolerance tests ,INSULIN ,RESEARCH funding ,SKELETAL muscle ,GLUCOSE clamp technique ,DISEASE complications - Abstract
Objective: Insulin must move from the blood to the interstitium to initiate signaling, yet access to the interstitium may be impaired in cases of insulin resistance, such as obesity. This study investigated whether consuming a short- and long-term high-fat diet (HFD) impairs insulin access to skeletal muscle, the major site of insulin-mediated glucose uptake.Methods: Male mongrel dogs were divided into three groups consisting of control diet (n = 16), short-term (n = 8), and long-term HFD (n = 8). Insulin sensitivity was measured with intravenous glucose tolerance tests. A hyperinsulinemic euglycemic clamp was performed in each animal at the conclusion of the study. During the clamp, lymph fluid was measured as a representation of the interstitial space to assess insulin access to muscle.Results: Short- and long-term HFD induced obesity and reduced insulin sensitivity. Lymph insulin concentrations were approximately 50% of plasma insulin concentrations under control conditions. Long-term HFD caused fasting plasma hyperinsulinemia; however, interstitial insulin concentrations were not increased, suggesting impaired insulin access to muscle.Conclusions: A HFD rapidly induces insulin resistance at the muscle and impairs insulin access under basal insulin concentrations. Hyperinsulinemia induced by a long-term HFD may be a compensatory mechanism necessary to maintain healthy insulin levels in muscle interstitium. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series.
- Author
-
Shankar, Sudha S., Vella, Adrian, Raymond, Ralph H., Staten, Myrlene A., Calle, Roberto A., Bergman, Richard N., Cao, Charlie, Chen, Danny, Cobelli, Claudio, Man, Chiara Dalla, Deeg, Mark, Dong, Jennifer Q., Lee, Douglas S., Polidori, David, Robertson, R. Paul, Ruetten, Hartmut, Stefanovski, Darko, Vassileva, Maria T., Weir, Gordon C., and Fryburg, David A.
- Subjects
GLUCOSE tolerance tests ,INSULIN ,PANCREATIC secretions ,GLUCOSE ,ARGININE ,TYPE 2 diabetes diagnosis ,BLOOD sugar ,INSULIN resistance ,ISLANDS of Langerhans ,TYPE 2 diabetes ,PREDIABETIC state ,RESEARCH evaluation ,RESEARCH funding ,WEIGHTS & measures ,CASE-control method ,DIAGNOSIS - Abstract
Objective: Standardized, reproducible, and feasible quantification of β-cell function (BCF) is necessary for the evaluation of interventions to improve insulin secretion and important for comparison across studies. We therefore characterized the responses to, and reproducibility of, standardized methods of in vivo BCF across different glucose tolerance states.Research Design and Methods: Participants classified as having normal glucose tolerance (NGT; n = 23), prediabetes (PDM; n = 17), and type 2 diabetes mellitus (T2DM; n = 22) underwent two standardized mixed-meal tolerance tests (MMTT) and two standardized arginine stimulation tests (AST) in a test-retest paradigm and one frequently sampled intravenous glucose tolerance test (FSIGT).Results: From the MMTT, insulin secretion in T2DM was >86% lower compared with NGT or PDM (P < 0.001). Insulin sensitivity (Si) decreased from NGT to PDM (∼50%) to T2DM (93% lower [P < 0.001]). In the AST, insulin secretory response to arginine at basal glucose and during hyperglycemia was lower in T2DM compared with NGT and PDM (>58%; all P < 0.001). FSIGT showed decreases in both insulin secretion and Si across populations (P < 0.001), although Si did not differ significantly between PDM and T2DM populations. Reproducibility was generally good for the MMTT, with intraclass correlation coefficients (ICCs) ranging from ∼0.3 to ∼0.8 depending on population and variable. Reproducibility for the AST was very good, with ICC values >0.8 across all variables and populations.Conclusions: Standardized MMTT and AST provide reproducible and complementary measures of BCF with characteristics favorable for longitudinal interventional trials use. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. Improved Performance of Dynamic Measures of Insulin Response Over Surrogate Indices to Identify Genetic Contributors of Type 2 Diabetes: The GUARDIAN Consortium.
- Author
-
Palmer, Nicholette D., Wagenknecht, Lynne E., Langefeld, Carl D., Nan Wang, Buchanan, Thomas A., Xiang, Anny H., Allayee, Hooman, Bergman, Richard N., Raffel, Leslie J., Chen, Yii-Der Ida, Haritunians, Talin, Fingerlin, Tasha, Goodarzi, Mark O., Taylor, Kent D., Rotter, Jerome I., Watanabe, Richard M., Bowden, Donald W., and Wang, Nan
- Subjects
PHYSIOLOGICAL effects of insulin ,TYPE 2 diabetes ,HOMEOSTASIS ,PHYSIOLOGICAL effects of glucose ,PHENOTYPES ,BLOOD sugar ,GLUCOSE tolerance tests ,INSULIN ,INSULIN resistance ,RESEARCH funding - Abstract
Type 2 diabetes (T2D) is a heterogeneous disorder with contributions from peripheral insulin resistance and β-cell dysfunction. For minimization of phenotypic heterogeneity, quantitative intermediate phenotypes characterizing basal glucose homeostasis (insulin resistance and HOMA of insulin resistance [HOMAIR] and of β-cell function [HOMAB]) have shown promise in relatively large samples. We investigated the utility of dynamic measures of glucose homeostasis (insulin sensitivity [SI] and acute insulin response [AIRg]) evaluating T2D-susceptibility variants (n = 57) in Hispanic Americans from the GUARDIAN Consortium (n = 2,560). Basal and dynamic measures were genetically correlated (HOMAB-AIRg: ρG = 0.28-0.73; HOMAIR-SI: ρG = -0.73 to -0.83) with increased heritability for the dynamic measure AIRg Significant association of variants with dynamic measures (P < 8.77 × 10(-4)) was observed. A pattern of superior performance of AIRg was observed for well-established loci including MTNR1B (P = 9.46 × 10(-12)), KCNQ1 (P = 1.35 × 10(-4)), and TCF7L2 (P = 5.10 × 10(-4)) with study-wise statistical significance. Notably, significant association of MTNR1B with AIRg (P < 1.38 × 10(-9)) was observed in a population one-fourteenth the size of the initial discovery cohort. These observations suggest that basal and dynamic measures provide different views and levels of sensitivity to discrete elements of glucose homeostasis. Although more costly to obtain, dynamic measures yield significant results that could be considered physiologically "closer" to causal pathways and provide insight into the discrete mechanisms of action. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Hepatic and Extrahepatic Insulin Clearance Are Differentially Regulated: Results From a Novel Model-Based Analysis of Intravenous Glucose Tolerance Data.
- Author
-
Polidori, David C., Bergman, Richard N., Chung, Stephanie T., and Sumner, Anne E.
- Subjects
- *
INSULIN , *GLUCOSE , *TREATMENT of diabetes , *INSULIN resistance , *C-peptide , *BIOLOGICAL models , *BLACK people , *BLOOD sugar , *FASTING , *GLUCOSE tolerance tests , *INTRAVENOUS injections , *LIVER , *RESEARCH funding - Abstract
Insulin clearance is a highly variable and important factor that affects circulating insulin concentrations. We developed a novel model-based method to estimate both hepatic and extrahepatic insulin clearance using plasma insulin and C-peptide profiles obtained from the insulin-modified frequently sampled intravenous glucose tolerance test. Data from 100 African immigrants without diabetes (mean age 38 years, body weight 81.7 kg, fasting plasma glucose concentration 83 mg/dL, and fasting insulin concentration 37 pmol/L) were used. Endogenous insulin secretion (calculated by C-peptide deconvolution) and insulin infusion rates were used as inputs to a new two-compartment model of insulin kinetics and hepatic and extrahepatic clearance parameters were estimated. Good agreement between modeled and measured plasma insulin profiles was observed (mean normalized root mean square error 6.8%), and considerable intersubject variability in parameters of insulin clearance among individuals was identified (the mean [interquartile range] for hepatic extraction was 25.8% [32.7%], and for extrahepatic insulin clearance was 20.7 mL/kg/min [11.7 mL/kg/min]). Parameters of insulin clearance were correlated with measures of insulin sensitivity and acute insulin response to glucose. The method described appears promising for future research aimed at characterizing variability in insulin clearance and the mechanisms involved in the regulation of insulin clearance. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity.
- Author
-
Mathur, Ruchi, Chua, Kathleen S., Mamelak, Mindy, Morales, Walter, Barlow, Gillian M., Thomas, Rita, Stefanovski, Darko, Weitsman, Stacy, Marsh, Zachary, Bergman, Richard N., and Pimentel, Mark
- Subjects
METHANOGENS ,ENTEROTYPES ,METHANE ,LOW density lipoproteins ,BLOOD sugar ,CHOLESTEROL metabolism ,METHANE analysis ,ANTIBIOTICS ,BREATH tests ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,OBESITY ,PREDIABETIC state ,RESEARCH ,RESEARCH funding ,EVALUATION research ,CASE-control method - Abstract
Objective: Methanogens colonizing the human gut produce methane and influence host metabolism. This study examined metabolic parameters in methane-producing subjects before and after antibiotic treatment.Methods: Eleven prediabetic methane-positive subjects (9F, 2M) with obesity (BMI 35.17 ± 7.71 kg/m(2) ) aged 47 ± 9 years were recruited. Subjects underwent breath testing, symptom questionnaire, oral glucose tolerance test (OGTT), lipid profile, and stool Methanobrevibacter smithii levels, gastric transit, and energy utilization analyses. After a 10-day antibiotic therapy (neomycin 500 mg bid/rifaximin 550 mg tid), all testing was repeated.Results: Baseline stool M. smithii levels correlated with breath methane (R = 0.7, P = 0.05). Eight subjects (73%) eradicated breath methane and showed reduced stool M. smithii (P = 0.16). After therapy, methane-eradicated subjects showed significant improvements in low-density lipoprotein (LDL) (P = 0.028), total cholesterol (P = 0.01), and insulin levels on OGTT (P = 0.05 at 120 minutes), lower blood glucose levels on OGTT (P = 0.054 at 90 minutes), significant reductions in bloating (P = 0.018) and straining (P = 0.059), and a trend toward lower stool dry weight. No changes were detected in gastric emptying time or energy harvest.Conclusions: Breath methane eradication and M. smithii reduction are associated with significant improvements in total cholesterol, LDL, and insulin levels and with lower glucose levels in prediabetic subjects with obesity. The underlying mechanisms require further elucidation. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
12. Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver.
- Author
-
Zheng, Dan, Ionut, Viorica, Mooradian, Vahe, Stefanovski, Darko, and Bergman, Richard N.
- Subjects
GLUCAGON-like peptide 1 ,SUGAR in the body ,BLOOD sugar ,INSULIN ,PEPTIDE hormones - Abstract
OBJECTIVE--Recent progress suggests that exenatide, a mimetic of glucagon-likepeptide-1 (GLP-1), might lower glycemia independent of increased β-cell response or reduced gastrointestinal motility. We aimed to investigate whether exenatide stimulates glucose turnover directly in insulin-responsive tissues dependent or independent of insulinemia. RESEARCH DESIGN AND METHODS--An intraportal glucose infusion clamp was used in dogs to measure glucose turnover to encompass potent activation of the putative glucose/GLP-1 sensor in the porto-hepatic circulation with exenatide. The modified glucose clamp was performed in the presence of postprandial hyperinsulinemia and hyperglycemia with exenatide (20 µg) or saline injected at 0 min. Furthermore, the role of hyperglycemia versus hyperinsulinemia in exenatide-mediated glucose disposal was studied. RESULTS--With hyperinsulinemia and hyperglycemia, exenatide produced a significant increase in total glucose turnover by ∼30%, as indicated by portal glucose infusion rate (saline 15.9 ± 1.6 vs. exenatide 20.4 ± 2.1 mg ⋅ kg[sup -1] ⋅ min[sup -l], P < 0.001), resulting from increased whole-body glucose disposal (R[sub d], ∼ 20%) and increased net hepatic uptake of exogenous glucose (∼ 80%). Reducing systemic hyperglycemia to euglycemia, exenatide still increased total glucose turnover by ∼ 20% (saline 13.2 ± 1.9 vs. exenatide 15.6 ± 2.1 mg ⋅ kg[sup -1] ⋅ min[sup -1], P < 0.05) in the presence of hyperinsulinemia, accompanied by smaller increments in R[sub d] (12%) and net hepatic uptake of exogenous glucose (45%). In contrast, reducing hyperinsulinemia to basal levels, exenatide-in-creased total glucose turnover was completely abolished despite hyperglycemia (saline 2.9 ± 0.6 vs. exenatide 2.3 ± 0.3 mg ⋅ kg[sup -1] ⋅ min[sup -1], P = 0.29). CONCLUSIONS--Exenatide directly stimulates glucose turnover by enhancing insulin-mediated whole-body glucose disposal and increasing hepatic uptake of exogenous glucose, contributing to its overall action to lower postprandial glucose excursions. Diabetes 58:352-359, 2009 [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
13. Comprehensive Association Study of Type 2 Diabetes and Related Quantitative Traits With 222 Candidate Genes.
- Author
-
Gaulton, Kyle J., Willer, Cristen J., Yun Li, Scott, Laura J., Conneely, Karen N., Jackson, Anne U., Duren, William L., Chines, Peter S., Narisu, Narisu, Bonnycastle, Lori L., Luo, Jingchun, Tong, Maurine, Sprau, Andrew G., Pugh, Elizabeth W., Doheny, Kimberly F., Valle, Timo T., Abecasis, Gonçalo R., Tuomilehto, Jaakko, Bergman, Richard N., and Collins, Francis S.
- Subjects
GENETICS of type 2 diabetes ,GENETIC polymorphisms ,HUMAN genetic variation ,DISEASE susceptibility ,PEOPLE with diabetes ,BLOOD sugar - Abstract
OBJECTIVE--Type 2 diabetes is a common complex disorder with environmental and genetic components. We used a candidate gene-based approach to identify single nucleotide polymorphism (SNP) variants in 222 candidate genes that influence susceptibility to type 2 diabetes. RESEARCH DESIGN AND METHODS--In a case-control study of 1,101 type 2 diabetic subjects and 1,174 control Finns who are normal glucose tolerant, we genotyped 3,531 tagSNPs and annotation-based SNPs and imputed an additional 7,498 SNPs, providing 99.9% coverage of common HapMap variants in the 222 candidate genes. Selected SNPs were genotyped in an additional 1,211 type 2 diabetic case subjects and 1,259 control subjects who are normal glucose tolerant, also From Finland. RESULTS--Using SNP- and gene-based analysis methods, we replicated previously reported SNP-type 2 diabetes associations in PPARG, KCNJ11, and SLC2A2; identified significant SNPs in genes with previously reported associations (ENPP1 [rs2021966, P = 0.00026] and NRF1 [rs1882095, P = 0.00096]); and implicated novel genes, including RAPGEF1 (rs4740283, P = 0.00013) and TP53 (rs1042522, Arg72Pro, P = 0.00086), in type 2 diabetes susceptibility. CONCLUSIONS--Our study provides an effective gene-based approach to association study design and analysis. One or more of the newly implicated genes may contribute to type 2 diabetes pathogenesis. Analysis of additional samples will be necessary to determine their effect on susceptibility. Diabetes 57:3136-3144, 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
14. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
- Author
-
Ionut, Viorica, Dan Zheng, Stefanovski, Darko, and Bergman, Richard N.
- Subjects
GLUCAGON ,TYPE 2 diabetes ,HORMONES ,GLUCOSE ,BLOOD sugar - Abstract
Exenatide is a long-acting glucagon-like peptide-1 (GLP-1) mimetic used in the treatment of type 2 diabetes. There is increasing evidence that GLP-1 can influence glycemia not only via pancreatic (insulinotropic and glucagon suppression) and gastric-emptying effects, but also via an independent mechanism mediated by portal vein receptors. The aim of our study was to investigate whether exenatide has an islet- and gastric-independent glycemia-reducing effect, similar to GLP-1. First, we administered mixed meals, with or without exenatide (20 µg sc) to dogs. Second, to determine whether exenatide-induced reduction in glycemia is independent of slower gastric emptying, in the same animals we infused glucose intraportally (to simulate meal test glucose appearance) with exenatide, exenatide + the intraportal GLP-1 receptor antagonist exendin-(9-39), or saline. Exenatide markedly decreased postprandial glucose: net 0- to 135-min area under the curve = +526 ± 315 and -536 ± 197 mg·dl
-1 ·min-1 with saline and exenatide, respectively (P < 0.05). Importantly, the decrease in plasma glucose occurred without a corresponding increase in post-prandial insulin but was accompanied by delayed gastric emptying and lower glucagon. Significantly lower glycemia was induced by intraportal glucose infusion with exenatide than with saline (92 ± 1 vs. 97 ± 1 mg/dl, P < 0.001) in the absence of hyperinsulinemia or glucagon suppression. The exenatide-induced lower glycemia was partly reversed by intraportal exendin-(9-39): 95 ± 3 and 92 ± 3 mg/dl with exenatide + antagonist and exenatide, respectively (P < 0.01). Our results suggest that, similar to GLP-1, exenatide lowers glycemia via a novel mechanism independent of islet hormones and slowing of gastric emptying. We hypothesize that receptors in the portal vein, via a neural mechanism, increase glucose clearance independent of islet hormones. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
15. OGTT-derived Measures of Insulin Sensitivity Are Confounded by Factors Other Than Insulin Sensitivity Itself.
- Author
-
Hücking, Katrin, Watanabe, Richard M., Stefanovski, Darko, and Bergman, Richard N.
- Subjects
INSULIN ,GLUCOSE tolerance tests ,ABSORPTION (Physiology) ,BLOOD sugar ,PANCREATIC beta cells ,SIMULATION methods & models ,MATHEMATICAL models ,METABOLISM - Abstract
The article assesses the accuracy of oral glucose tolerance test (OGTT)-derived measures of insulin sensitivity which are confounded by factors including rate of glucose absorption and/or β-cell function. Among the methods for the quantification of insulin sensitivity, based upon fasting blood measurements, applicable in large populations are the homeostasis model assessment (HOMA) and the quantitative insulin sensitivity check index (QUICKI). Mathematical simulation of in vivo glucose and insulin metabolism during such a test is discussed.
- Published
- 2008
- Full Text
- View/download PDF
16. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia.
- Author
-
Kim, Stella P., Catalano, Karyn J., Hsu, Isabel R., Chiu, Jenny D., Richey, Joyce M., and Bergman, Richard N.
- Subjects
FATTY acids ,INSULIN resistance ,OBESITY ,INSULIN shock ,DIET ,BLOOD sugar ,HORMONES - Abstract
Obesity is strongly associated with hyperinsulinemia and insulin resistance, both primary risk factors for type 2 diabetes. It has been thought that increased fasting free fatty acids (FFA) may be responsible for the development of insulin resistance during obesity, causing an increase in plasma glucose levels, which would then signal for compensatory hyperinsulinemia. But when obesity is induced by fat feeding in the dog model, there is development of insulin resistance and a marked increase in fasting insulin despite constant fasting FFA and glucose. We examined the 24-h plasma profiles of FFA, glucose, and other hormones to observe any potential longitudinal postprandial or nocturnal alterations that could lead to both insulin resistance and compensatory hyperinsulinemia induced by a high-fat diet in eight normal dogs. We found that after 6 wk of a high-fat, hypercaloric diet, there was development of significant insulin resistance and hyperinsulinemia as well as accumulation of both subcutaneous and visceral fat without a change in either fasting glucose or postprandial glucose. Moreover, although there was no change in fasting FFA, there was a highly significant increase in the nocturnal levels of FFA that occurred as a result of fat feeding. Thus enhanced nocturnal FFA, but not glucose, may be responsible for development of insulin resistance and fasting hyperinsulinemia in the fat-fed dog model. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
17. Frequency of hypoglycaemia during the intravenous glucose tolerance test in overweight children.
- Author
-
Cruz, Martha L., Weigensberg, Marc J., Bergman, Richard N., and Goran, Michael I.
- Subjects
HYPOGLYCEMIA ,GLUCOSE tolerance tests ,OVERWEIGHT children ,BLOOD sugar ,BLOOD testing - Abstract
The study aimed to assess the frequency of hypoglycaemia during the insulin-modified, frequently sampled intravenous glucose tolerance test (FSIVGTT) in overweight Hispanic children. The study included 210 children, mean age=11±1.7 years, BMI percentile=97.2±2.9 who where enrolled in a longitudinal study to explore risk factors for type 2 diabetes. Two fasting blood samples were collected to determine basal glucose and insulin concentrations. At time 0, glucose (0.3 g/kg body weight) was administered intravenously. Eleven blood samples were collected until 180 min post glucose injection. Insulin (0.02 U/kg body weight) was injected intravenously at 20 min. Plasma was analyzed for glucose and insulin and used for the determination of insulin sensitivity. Hypoglycaemia, defined as a plasma glucose<50 mg/dl, was observed in one asymptomatic subject (<0.5% subjects). In addition, only 1.9% of subjects (n=4) had plasma glucose<60 mg/dl at any time during the FSIVGTT. The frequency of hypoglycaemia during the insulin modified FSIVGTT is very low in overweight Hispanic youth. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
18. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs.
- Author
-
Ader, Marilyn, Kim, Stella P., Catalano, Karyn J., Ionut, Viorica, Hucking, Katrin, Richey, Joyce M., Kabir, Morvarid, and Bergman, Richard N.
- Subjects
ANTIPSYCHOTIC agents ,DIABETES ,HYPERGLYCEMIA ,BLOOD sugar ,OBESITY - Abstract
Atypical antipsychotics have been linked to weight gain, hyperglycemia, and diabetes. We examined the effects of atypical antipsychotics olanzapine (OLZ) and risperidone (RIS) versus placebo on adiposity, insulin sensitivity (S(I)), and pancreatic beta-cell compensation. Dogs were fed ad libitum and given OLZ (15 mg/day; n = 10), RIS (5 mg/day; n = 10), or gelatin capsules (n = 6) for 4-6 weeks. OLZ resulted in substantial increases in adiposity: increased total body fat (+91 +/- 20%; P = 0.000001) reflecting marked increases in subcutaneous (+106 +/- 24%; P = 0.0001) and visceral (+84 +/- 22%; P = 0.000001) adipose stores. Changes in adiposity with RIS were not different from that observed in the placebo group (P > 0.33). Only OLZ resulted in marked hepatic insulin resistance (hepatic S(I) [pre- versus postdrug]: 6.05 +/- 0.98 vs. 1.53 +/- 0.93 dl . min(-1) . kg(-1)/[microU/ml], respectively; P = 0.009). beta-Cell sensitivity failed to upregulate during OLZ (pre-drug: 1.24 +/- 0.15, post-drug: 1.07 +/- 0.25 microU . ml(-1)/[mg/dl]; P = 0.6). OLZ-induced beta-cell dysfunction was further demonstrated when beta-cell compensation was compared with a group of animals with adiposity and insulin resistance induced by moderate fat feeding alone (+8% of calories from fat; n = 6). These results may explain the diabetogenic effects of atypical antipsychotics and suggest that beta-cell compensation is under neural control. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
19. Effects of Exercise Training on Glucose Homeostasis.
- Author
-
Boulé, Normand G., Weisnagel, S. John, Lakka, Timo A., Tremblay, Angelo, Bergman, Richard N., Rankinen, Tuomo, Leon, Arthur S., Skinner, James S., Wilmore, Jack H., Rao, D.C., and Bouchard, Claude
- Subjects
TRAINING ,HEALTH ,GLUCOSE tolerance tests ,BLOOD testing ,BLOOD sugar - Abstract
OBJECTIVE -- To determine the effect of a 20-week endurance training program in healthy, previously sedentary participants on measures derived from an intravenous glucose tolerance test (IVGTT). RESEARCH DESIGN AND METHODS -- An IVGTT was performed before and after a standardized training program in 316 women and 280 men (173 blacks and 423 whites). Participants exercised on cycle ergometers 3 days per week for 60 sessions. The exercise intensity was progressively increased from 55% VO[sub 2max] for 30 min per session to 75% VO[sub 2max] for 50 min per session. RESULTS -- Mean insulin sensitivity increased by 10% (P < 0.001) following the intervention, but the variability in the changes was high. Men had larger improvements than women (P = 0.02). Improvements in fasting insulin were transitory, disappearing 72 h after the last bout of exercise. There were also significant mean increases in the glucose disappearance index (3%, P = 0.02) and in glucose effectiveness (11%, P < 0.001), measures of glucose tolerance and of the capacity of glucose to mediate its own disposal, respectively. The acute insulin response to glucose, a measure of insulin secretion, increased by 7% in the quartile with the lowest baseline glucose tolerance and decreased by 14% in the quartile with the highest baseline glucose tolerance (P < 0.001). The glucose area below fasting levels during the IVGTT was reduced by 7% (P = 0.02). CONCLUSIONS -- Although the effects of structured regular exercise were highly variable, there were improvements in virtually all IVGTT-derived variables. In the absence of substantial weight loss, regular exercise is required for sustained improvements in glucose homeostasis. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
20. Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study.
- Author
-
Palmer, Nicholette D., Bento, Jennifer L., Mychaleckyj, Josyf C., Langefeld, Carl D., Campbell, Joel K., Norris, Jill M., Haffner, Stephen M., Bergman, Richard N., Bowden, Donald W., and insulin resistance atherosclerosis study (IRAS) family study
- Subjects
PROTEIN-tyrosine phosphatase ,GENES ,PROTEINS ,INSULIN ,HOMEOSTASIS ,GLUCOSE metabolism ,BLOOD sugar ,COMPARATIVE studies ,GENE mapping ,GENETIC polymorphisms ,HISPANIC Americans ,INSULIN resistance ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,PHENOTYPES ,EVALUATION research - Abstract
Protein tyrosine phosphatase (PTP)-1B, encoded by the PTPN1 gene, catalyzes the dephosphorylation of proteins at tyrosyl residues. PTP-1B has been implicated in negatively regulating insulin signaling by dephosphorylating the phosphotyrosine residues of the insulin receptor. The genetic contribution of PTPN1 to measures of glucose homeostasis has been assessed in 811 Hispanic subjects from the Insulin Resistance Atherosclerosis Study Family Study (IRASFS). Thirty-five single nucleotide polymorphisms (SNPs) spanning 161 kb and containing the PTPN1 gene were genotyped and tested for association. All 20 SNPs with minor allele frequencies >0.1 in a single haplotype block covering the PTPN1 genomic sequence show significant association with the insulin sensitivity index (S(i)) (P = 0.044-0.003) and fasting glucose (P = 0.029 to <0.001). In contrast, there is no evidence for association of PTPN1 polymorphisms with acute insulin response (a measure of beta-cell function). Haplotype analysis of eight SNP haplotypes that have independently been shown to be associated with type 2 diabetes risk and protection in Caucasian type 2 diabetic subjects are associated with lower (P = 0.007) and higher (P = 0.0002) S(i) and higher (P = 0.00007) and lower (P = 0.001) fasting glucose, respectively, in the IRASFS. This comprehensive genetic analysis of PTPN1 reveals significant association with metabolic traits consistent with the proposed in vivo role for the PTP-1B protein. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
21. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake.
- Author
-
Dea, Melvin K., Hamilton-Wessler, Marianthe, Ader, Marilyn, Moore, Donna, Schäffer, Lauge, Loftager, Mette, Vølund, Aage, Bergman, Richard N., Schäffer, Lauge, and Vølund, Aage
- Subjects
INSULIN ,ALBUMINS ,ANIMAL experimentation ,BLOOD plasma ,BLOOD sugar ,BLOOD volume ,CARRIER proteins ,COMPARATIVE studies ,DOGS ,DYNAMICS ,GLUCOSE ,INSULIN derivatives ,LIVER ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,SERUM albumin ,EVALUATION research - Abstract
NN304 [Lys(B29)-tetradecanoyl des(B30) human insulin] is a potentially therapeutic insulin analog designed to exhibit protracted glucose-lowering action. In dogs with infusion rates similar to insulin itself, NN304 exhibits similar glucose uptake (R(d)) stimulation with delayed onset of action. This compartmental modeling study was to determine if NN304 action could be accounted for by the approximately 2% unbound NN304 concentration. NN304 (or human insulin) (n = 6 each) was infused at 10.2 pmol center dot min(-1) center dot kg(-1) under euglycemic clamp conditions in anesthetized dogs. NN304 appearance in lymph, representing interstitial fluid (ISF), was slow compared with insulin (t(1/2) = 70 +/- 7 vs. 14 +/- 1 min, P < 0.001). R(d) was highly correlated with the ISF concentration for insulin and NN304 (r = 0.86 and 0.93, respectively), suggesting that slow transendothelial transport (TET) is responsible for sluggish NN304 action. Insulin and NN304 concentration data were fit to a two-compartment (plasma and ISF) model. NN304 plasma elimination and TET were reduced to 10 and 7% of insulin, respectively. Thus, there was reduction of NN304 transport, but not to the degree expected. In ISF, there was no reduction in NN304 elimination. Thus, this acylated insulin analog demonstrates blunted kinetics in plasma, and full efficacy in the compartment of action, ISF. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
22. Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion.
- Author
-
Hamilton-Wessler, Marianthe, Ader, Marilyn, Dea, Melvin K., Moore, Donna, Loftager, Mette, Markussen, Jan, and Bergman, Richard N.
- Subjects
INSULIN ,HINDLIMB ,FATTY acids ,ANIMAL experimentation ,BIOLOGICAL transport ,BLOOD flow measurement ,BLOOD sugar ,CAPILLARIES ,CARRIER proteins ,CELL receptors ,COMPARATIVE studies ,DIFFUSION ,DOGS ,ENDOTHELIUM ,EXTRACELLULAR space ,FEMORAL artery ,HEMODYNAMICS ,INSULIN derivatives ,LEG ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,EVALUATION research ,SKELETAL muscle ,GLUCOSE clamp technique - Abstract
A defect in transcapillary transport of insulin in skeletal muscle and adipose tissue has been proposed to play a role in the insulin resistance that leads to type 2 diabetes, yet the mechanism of insulin transfer across the capillary endothelium from plasma to interstitium continues to be debated. This study examined in vivo the interstitial appearance of insulin in hindlimb using the fatty acid acylated insulin analog Lys(B29)-tetradecanoyl des-(B30) human insulin, or NN304, as a marker for insulin transport. If the insulin transport were a saturable process, then "swamping" the capillary endothelial insulin receptors with native insulin would suppress the subsequent appearance in interstitial fluid of the insulin analog NN304. This analog binds to insulin receptors with an affinity of about 50% of native insulin. Experimental conditions established a physiologic NN304 dose in the absence or presence of pharmacologic and saturating concentrations of regular human insulin. Euglycemic clamps were performed in dogs under inhalant anesthesia with deep hindlimb lymphatic sampling, representative of skeletal muscle interstitial fluid (ISF). In group 1 (n = 8), NN304 alone was infused (3.6 pmol center dot min(-1) center dot kg(-1)) from 60 to 360 min. In group 2 (n = 6), starting at time 0, human insulin was infused at a pharmacologic dose (60 pmol center dot min(-1) center dot kg(-1)) with the addition of NN304 infusion (3.6 pmol center dot min(-1) center dot kg(-1)) from 60 to 360 min. In group 3 (n = 4), the human insulin infusion was increased to a saturating dose (120 pmol center dot min(-1) center dot kg(-1)). Pharmacologic insulin infusion (group 2) established steady-state human insulin concentrations of 6,300 plus minus 510 pmol/l in plasma and 5,300 plus minus 540 pmol/l in ISF. Saturating insulin infusion (group 3) achieved steady-state human insulin concentrations of 22,000 plus minus 1,800 pmol/l in plasma and 19,000 plus minus 1,500 pmol/l in ISF. Total (bound and unbound) NN304 plasma concentrations rose from a steady state of 1,900 plus minus 110 (group 1) to 2,400 plus minus 200 pmol/l (group 2) and 3,100 plus minus 580 pmol/l (group 3), consistent with a competition-driven decline in NN304 clearance from plasma as the human insulin level increased (P < 0.05 by ANOVA). Steady-state interstitial NN304 concentrations also rose with increasing human insulin levels but did not achieve significance in comparison with analog alone (162 plus minus 15 vs. 196 plus minus 22 and 241 plus minus 53 pmol/l for group 1 versus groups 2 and 3, respectively; P = 0.20), yet the steady-state plasma:ISF ratio for NN304 remained essentially unchanged in the absence and presence of elevated human insulin levels (12.6 plus minus 1.2 vs. 12.4 plus minus 0.5 and 13.1 plus minus 1.5 for group 1 versus groups 2 and 3, respectively; P = 0.93). Last, NN304 rate of appearance in interstitial fluid (i.e., half-time to steady state) was similar between groups; mean half-time of 92 plus minus 4 min (NS between groups). In conclusion, appearance of the insulin analog NN304 in skeletal muscle interstitial fluid was constant whether in the absence or presence of human insulin concentrations sufficient to saturate the endothelial insulin receptors. These findings support the hypothesis, provided that the mechanism of insulin and NN304 transcapillary transport is similar, that transcapillary transport of insulin in skeletal muscle occurs primarily via a nonsaturable process such as passive diffusion via a paracellular or transcellular route. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
23. Hypoglycemic detection does not occur in the hepatic artery or liver: findings consistent with a portal vein glucosensor locus.
- Author
-
Hevener, Andrea L., Bergman, Richard N., Donovan, Casey M., Hevener, A L, Bergman, R N, and Donovan, C M
- Subjects
- *
HYPOGLYCEMIA , *BLOOD sugar , *LABORATORY dogs , *LABORATORY animals , *SUGAR in the body - Abstract
Our laboratory has previously demonstrated that hypoglycemic detection occurs in the portal vein, not the liver. To ascertain whether hypoglycemic detection may also occur in the hepatic artery, normoglycemia was established across the liver via a localized hepatic artery glucose infusion. Male mongrel dogs (n = 7) were infused with insulin (5.0 mU x kg(-1) x min(-1)) via the jugular vein to induce systemic hypoglycemia. Animals participated in two hyperinsulinemic-hypoglycemic clamp experiments distinguished by the site of glucose infusion. During the liver irrigation protocol, glucose was infused via the hepatic artery (HA protocol) to maintain liver normoglycemia as systemic glucose concentrations were systematically lowered over 260 min (nadir = 2.2 +/- 0.01 mmol/l). During control experiments, glucose was infused peripherally (PER protocol) to control reductions in blood glucose. Arterial glucose concentrations were not significantly different at any time between the two protocols (P = 0.73). Hepatic artery and liver glucose concentrations were significantly elevated in the HA versus PER protocol throughout the duration of the progressive hyperinsulinemic-hypoglycemic clamp. During the PER protocol, epinephrine and norepinephrine concentrations increased significantly above basal values (0.53 +/- 0.06 and 0.85 +/- 0.2 nmol/l, respectively) to plateaus of 4.4 +/- 0.86 (P = 0.0001) and 3.6 +/- 0.69 nmol/l (P = 0.001), respectively. There were no significant differences between the two protocols in the epinephrine (P = 0.81) and the norepinephrine (P = 0.68) response to hypoglycemia. The current findings indicate that glucosensors important to hypoglycemic detection do not reside in the hepatic artery. Furthermore, these data confirm our previous findings that glucosensors important to hypoglycemic detection are not present in the liver, but are in fact localized to the portal vein. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
24. Inhibition of lipolysis causes suppression of endogenous glucose production independent of....
- Author
-
Mittelman, Steven D. and Bergman, Richard N.
- Subjects
- *
BLOOD sugar , *LIPOLYSIS , *INSULIN - Abstract
Reports the suppression of endogenous glucose production (EGP) by the inhibition of lipolysis under constant insulin in dogs. Difference in the sensitivity of free fatty acid and EGP suppression; Prevention of EGP reduction in lyposin control experiments; Increase of catecholamine and glucagon levels during N[sup 6]-cyclohexyladenosine infusion.
- Published
- 2000
25. B-Cell Compensation for Insulin Resistance Can Occur Absent Any Change in Basal or 24-Hour Plasma Glucose Levels.
- Author
-
Stefanovski, Darko, Woolcott, Orison, Lottati, Maya, Zheng, Dan, Harrison, Lisa N., Ionut, Viorica, Kim, Stella P., Hsu, Isabel, Chiu, Jenny, Catalano, Karyn, Kolka, Cathryn, Richey, Joyce M., and Bergman, Richard N.
- Subjects
PANCREATIC beta cells ,INSULIN resistance ,BLOOD sugar ,BLOOD plasma ,HYPERGLYCEMIA ,GLUCOSE tolerance tests - Abstract
Increased insulin is the primary mechanism of compensation for changes in insuliln resistance which may occur due to environmental causes. Yet, the mechanism which is responsible for the compensatory hyperinsulinemia is not clarified. One obvious candidate is elevated glucose which could arise from reduced glucose tolerance secondary to insulin resistance. We asked if even subtle hyperglycemia accompanies the compensatory hyperinsulinemia of high fat feeding. Male mongrel dogs (n=9) were fed the hypercaloric high fat diet (∼5400kcal/d, 53% kcal from fat) for 6 weeks. The Frequently Sampled Intravenous Glucose Tolerance (FSIGT) test was utilized to assess changes in glucose homeostasis at weeks 0 (pre-diet), 2, 4 and 6 (W:0; W:2; W:4; W:6, respectively). Basal glucose and FFAs were obtained at three time intervals during the day (8-8:30am, 6-8 pm, and 2-4 am) at W:0, and W:6. Due to the diet, body weight was significantly increased by W:2 (+2.5+/-0.33 kg, P<.001) and remained elevated throughout the entire study (W:6 + 1.79 kg, P<0.001). Within two weeks of fat feeding, insulin sensitivity (SI) dramatically decreased by 45% (5.6+/-0.9 vs. 3.1+/-1.2; W:0 vs. W:2 P=.04). At W:6, SI decreased by 66% (1.9+/-1.3, P=-.006). AIRg rose modestly by W:2 (14%, P=NS), increasing by 46% (P<0.02) and 59% (P0.13) over 6 weeks. Importantly, there was no increase in measured glucose at any of the three time periods between weeks 0 and 6 (P>0.68, P>0.56, P>0.18). But, we observed a trend for elevated FFA at basal (P=0.06) and highly signficant increase of FFA in the middle of the night by week 6 (0.42 +/- 0.7 to 0.75 +/- 0.04 mM, P<0.001). Hyperinsulinemic compensation for insuliln resistance can occur absent any changes in plasma glucose levels, and may implicate FFA, particularly at night, as being responsible for b-cell compensation. ADA-Funded Research [ABSTRACT FROM AUTHOR]
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.